We recently compiled a list of the 8 Magnificent Dividend Growth Stocks to Buy Now. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other magnificent dividend growth stocks.

This year, dividend stocks have underperformed compared to the broader market, largely because tech stocks have captured most of the attention. The Dividend Aristocrats Index, which tracks companies with at least 25 consecutive years of dividend growth, has risen by nearly 10% year-to-date, compared to the broader market’s almost 24% gain. Despite this, dividend stocks remain a reliable choice for investors, consistently delivering returns to shareholders regardless of market conditions.

Investors tend to favor companies with strong histories of dividend growth. This preference stems from the fact that such stocks have reported solid long-term returns, often outperforming the broader market. According to a report by RMB Capital, dividend growers and initiators delivered an annual average return of 9.62% from 1972 to 2018, compared with a 2.40% return of the companies that did not pay dividends. Moreover, the broader market returned 7.30% during this period, underperforming dividend growers. The report further mentioned that companies with a track record of increasing dividends have demonstrated their ability to not only maintain but also grow payouts, even during market downturns. From a portfolio management standpoint, dividend growth portfolios offer good diversification, as companies with consistent dividend growth are typically spread across various industries. This provides an edge over portfolios that prioritize high dividend yields, which are often concentrated in mature sectors such as utilities and, before 2007, financials.

Also read: Dividend Contenders List: Top 15

Analysts suggest including dividend stocks in income portfolios. This recommendation is bolstered by the fact that several leading tech companies introduced dividend policies this year and are likely to sustain dividend growth over time, supported by their strong cash flows. David Harrell, editor of Morningstar’s DividendInvestor newsletter, shared his insights on dividend growth during a recent interview with the firm. Here are some comments from the analyst:

“You see headlines about dividend increases. That’s generally viewed as positive. There’s this whole idea of dividend growth investing by identifying companies that are growing their dividends at a regular pace. That’s indicative of companies with strong growing earnings. That’s considered positive. There’s also this idea that dividend stocks can be defensive in recessionary periods.”

While dividend stocks have shown slower performance this year, companies continue to raise their dividends steadily. A recent report from S&P Dow Jones Indices revealed that 480 dividend hikes were recorded in Q3 2024, up from 448 in Q3 2023, reflecting a 7.1% year-over-year growth. The total value of these increases for the quarter reached $14.1 billion. The report also mentioned that over the past 12 months, total dividend increases amounted to $74.7 billion, marking a rise from $63.9 billion in the previous 12-month period.

Our Methodology:

For this article, we scanned the list of Dividend Aristocrats, which are the companies that have raised their payouts for 25 consecutive years or more. From that list, we picked 8 companies with the highest 5-year annual average dividend growth rates. The stocks are ranked in ascending order of their annual average dividend growth in the past five years.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

Abbott Laboratories (NYSE:ABT)

5-Year Average Annual Dividend Growth Rate: 11.44%

Abbott Laboratories (NYSE:ABT) ranks fifth on our list of the best dividend aristocrat stocks. The American medical device company is attracting investor interest after a jury ruled in its favor, along with a Reckitt unit, clearing both of liability in a lawsuit concerning their infant formulas for premature babies. since the start of 2024, the stock has surged by over 5% and its 12-month return came in at 19.2%.

Abbott Laboratories (NYSE:ABT)  gains significant advantages from its diversified business model, which opens numerous avenues for growth and enables it to generate income from a range of sources. In the third quarter of 2024, the company reported revenue of over $10.6 billion, which showed a 5% growth from the same period last year. The company gains significant advantages from its collaborations with major industry players. In August, Abbott revealed a unique global partnership with Medtronic, aimed at integrating Abbott’s top-tier continuous glucose monitoring (CGM) system with Medtronic’s insulin delivery devices.

Abbott Laboratories (NYSE:ABT) is seeing robust growth in its medical device segment, with especially high demand for its continuous glucose monitors, which assist individuals with diabetes in managing their glucose levels effectively. In the most recent quarter, its medical device segment reported $4.7 billion in revenues, up from $4.3 billion in the prior year period.

In the past five years, Abbott Laboratories (NYSE:ABT) has raised its dividends at an annual average rate of 11.44%. Moreover, it is one of the best dividend aristocrat stocks on our list with 52 consecutive years of dividend growth under its belt. The company pays a quarterly dividend of $0.55 per share and has a dividend yield of 1.90%, as of November 14.

Overall ABT ranks 5th on our list of the magnificent dividend growth stocks to buy now. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.